Serum anti-Müllerian hormone levels in precocious puberty girls according to stage of GnRH agonist treatment

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Few studies have investigated the long-term effects of gonadotropin-releasing hormone (GnRH) agonist treatment on the reproductive function of central precocious puberty (CPP) girls. In this cross-sectional study, we assessed the ovarian function by analyzing the serum anti-Müllerian hormone (AMH) levels of CPP girls. Our study included 505 CPP girls subdivided into 5 groups according to the GnRH agonist treatment stage: group A (before treatment, n = 98), group B (3 months after initiation, n = 103), group C (12 months after initiation, n = 101), group D (24 months after initiation, n = 101), and group E (6 months after discontinuation, n = 102). We compared the serum AMH levels of the CPP girls with those of 100 bone age-matched controls (before treatment: n = 55; after discontinuation: n = 45). At baseline, the mean AMH level of the CPP girls was 5.9 ± 3.6 ng/mL. The mean AMH level after 3 months of the GnRH agonist treatment was lower (4.7 ± 3.2 ng/mL, P = 0.047) than that at baseline and recovered after 12 months of treatment. Six months after discontinuation, the AMH levels were similar to those at pre-treatment. Before and after the GnRH agonist treatment, the AMH levels were similar to those of the bone agematched controls. In the precocious puberty girls, the AMH levels based on the GnRH agonist treatment stage were all within the normal reference range. The results of this study suggest that GnRH agonist treatment has no adverse effects on the reproductive function.

Original languageEnglish
Pages (from-to)475-479
Number of pages5
JournalJournal of Korean Medical Science
Volume32
Issue number3
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Precocious Puberty
Gonadotropin-Releasing Hormone
Hormones
Serum
Therapeutics
Reference Values
Bone and Bones
Cross-Sectional Studies
Central Precocious Puberty

Keywords

  • Anti-Müllerian hormone
  • Gonadotropin-releasing hormone agonist
  • Ovarian reserve
  • Precocious
  • Puberty

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{915e306650de4e2f823bb2365fdbc476,
title = "Serum anti-M{\"u}llerian hormone levels in precocious puberty girls according to stage of GnRH agonist treatment",
abstract = "Few studies have investigated the long-term effects of gonadotropin-releasing hormone (GnRH) agonist treatment on the reproductive function of central precocious puberty (CPP) girls. In this cross-sectional study, we assessed the ovarian function by analyzing the serum anti-M{\"u}llerian hormone (AMH) levels of CPP girls. Our study included 505 CPP girls subdivided into 5 groups according to the GnRH agonist treatment stage: group A (before treatment, n = 98), group B (3 months after initiation, n = 103), group C (12 months after initiation, n = 101), group D (24 months after initiation, n = 101), and group E (6 months after discontinuation, n = 102). We compared the serum AMH levels of the CPP girls with those of 100 bone age-matched controls (before treatment: n = 55; after discontinuation: n = 45). At baseline, the mean AMH level of the CPP girls was 5.9 ± 3.6 ng/mL. The mean AMH level after 3 months of the GnRH agonist treatment was lower (4.7 ± 3.2 ng/mL, P = 0.047) than that at baseline and recovered after 12 months of treatment. Six months after discontinuation, the AMH levels were similar to those at pre-treatment. Before and after the GnRH agonist treatment, the AMH levels were similar to those of the bone agematched controls. In the precocious puberty girls, the AMH levels based on the GnRH agonist treatment stage were all within the normal reference range. The results of this study suggest that GnRH agonist treatment has no adverse effects on the reproductive function.",
keywords = "Anti-M{\"u}llerian hormone, Gonadotropin-releasing hormone agonist, Ovarian reserve, Precocious, Puberty",
author = "Hyo-Kyoung Nam and Kim, {Hye Ryun} and Young-Jun Rhie and Lee, {Kee Hyoung}",
year = "2017",
month = "1",
day = "1",
doi = "10.3346/jkms.2017.32.3.475",
language = "English",
volume = "32",
pages = "475--479",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "3",

}

TY - JOUR

T1 - Serum anti-Müllerian hormone levels in precocious puberty girls according to stage of GnRH agonist treatment

AU - Nam, Hyo-Kyoung

AU - Kim, Hye Ryun

AU - Rhie, Young-Jun

AU - Lee, Kee Hyoung

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Few studies have investigated the long-term effects of gonadotropin-releasing hormone (GnRH) agonist treatment on the reproductive function of central precocious puberty (CPP) girls. In this cross-sectional study, we assessed the ovarian function by analyzing the serum anti-Müllerian hormone (AMH) levels of CPP girls. Our study included 505 CPP girls subdivided into 5 groups according to the GnRH agonist treatment stage: group A (before treatment, n = 98), group B (3 months after initiation, n = 103), group C (12 months after initiation, n = 101), group D (24 months after initiation, n = 101), and group E (6 months after discontinuation, n = 102). We compared the serum AMH levels of the CPP girls with those of 100 bone age-matched controls (before treatment: n = 55; after discontinuation: n = 45). At baseline, the mean AMH level of the CPP girls was 5.9 ± 3.6 ng/mL. The mean AMH level after 3 months of the GnRH agonist treatment was lower (4.7 ± 3.2 ng/mL, P = 0.047) than that at baseline and recovered after 12 months of treatment. Six months after discontinuation, the AMH levels were similar to those at pre-treatment. Before and after the GnRH agonist treatment, the AMH levels were similar to those of the bone agematched controls. In the precocious puberty girls, the AMH levels based on the GnRH agonist treatment stage were all within the normal reference range. The results of this study suggest that GnRH agonist treatment has no adverse effects on the reproductive function.

AB - Few studies have investigated the long-term effects of gonadotropin-releasing hormone (GnRH) agonist treatment on the reproductive function of central precocious puberty (CPP) girls. In this cross-sectional study, we assessed the ovarian function by analyzing the serum anti-Müllerian hormone (AMH) levels of CPP girls. Our study included 505 CPP girls subdivided into 5 groups according to the GnRH agonist treatment stage: group A (before treatment, n = 98), group B (3 months after initiation, n = 103), group C (12 months after initiation, n = 101), group D (24 months after initiation, n = 101), and group E (6 months after discontinuation, n = 102). We compared the serum AMH levels of the CPP girls with those of 100 bone age-matched controls (before treatment: n = 55; after discontinuation: n = 45). At baseline, the mean AMH level of the CPP girls was 5.9 ± 3.6 ng/mL. The mean AMH level after 3 months of the GnRH agonist treatment was lower (4.7 ± 3.2 ng/mL, P = 0.047) than that at baseline and recovered after 12 months of treatment. Six months after discontinuation, the AMH levels were similar to those at pre-treatment. Before and after the GnRH agonist treatment, the AMH levels were similar to those of the bone agematched controls. In the precocious puberty girls, the AMH levels based on the GnRH agonist treatment stage were all within the normal reference range. The results of this study suggest that GnRH agonist treatment has no adverse effects on the reproductive function.

KW - Anti-Müllerian hormone

KW - Gonadotropin-releasing hormone agonist

KW - Ovarian reserve

KW - Precocious

KW - Puberty

UR - http://www.scopus.com/inward/record.url?scp=85013897743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013897743&partnerID=8YFLogxK

U2 - 10.3346/jkms.2017.32.3.475

DO - 10.3346/jkms.2017.32.3.475

M3 - Article

C2 - 28145651

AN - SCOPUS:85013897743

VL - 32

SP - 475

EP - 479

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 3

ER -